Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48


Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.

Jung SY, Hwang S, Clarke JM, Bauer TM, Keedy VL, Lee H, Park N, Kim SJ, Lee JI.

Invest New Drugs. 2019 Jul 13. doi: 10.1007/s10637-019-00835-y. [Epub ahead of print]


Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG.

J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.


Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.


Linear Accelerator-Based Stereotactic Radiosurgery for Cranial Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath Tumor: Case Report and Review of the Literature.

Fenlon JB, Khattab MH, Ferguson DC, Luo G, Keedy VL, Chambless LB, Kirschner AN.

World Neurosurg. 2019 Mar;123:123-127. doi: 10.1016/j.wneu.2018.11.231. Epub 2018 Dec 7. Review.


BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]


Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.

Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL.

Med Oncol. 2018 Aug 20;35(10):131. doi: 10.1007/s12032-018-1193-5.


Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.


The current landscape of early drug development for patients with sarcoma in the immunotherapy era.

Sebio A, Wilky BA, Keedy VL, Jones RL.

Future Oncol. 2018 May;14(12):1197-1211. doi: 10.2217/fon-2017-0565. Epub 2018 Apr 27. Review.


First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.

Keedy VL, Lenz HJ, Saltz L, Whisenant JG, Berlin JD, Camacho LH.

Invest New Drugs. 2018 Oct;36(5):860-868. doi: 10.1007/s10637-018-0567-z. Epub 2018 Jan 29.


First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.


The Current Landscape of Early Drug Development for Patients With Sarcoma.

Wilky BA, Jones RL, Keedy VL.

Am Soc Clin Oncol Educ Book. 2017;37:807-810. doi: 10.14694/EDBK_174701. Review.


PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.


Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, Lenderking W, Ye X, Speck RM, Lackman RD, Bukata SV, Healey JH, Keedy VL, Anthony SP, Wagner AJ, Von Hoff DD, Singh AS, Becerra CR, Hsu HH, Lin PS, Tap WD.

Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.


Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.

Sethi TK, Keedy VL.

Curr Treat Options Oncol. 2016 Feb;17(2):11. doi: 10.1007/s11864-015-0382-0.


Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.


nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.

Lammers PE, Lu B, Horn L, Shyr Y, Keedy V.

Oncologist. 2015 May;20(5):491-2. doi: 10.1634/theoncologist.2015-0030. Epub 2015 Apr 6.


Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC.

Int J Nanomedicine. 2015 Feb 10;10:1201-9. doi: 10.2147/IJN.S62911. eCollection 2015. Erratum in: Int J Nanomedicine. 2019 Jul 24;14:5751-5752.


A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.

Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE.

Oncologist. 2015 Feb;20(2):105-6. doi: 10.1634/theoncologist.2014-0327. Epub 2015 Jan 23.


Cytotoxic chemotherapy for adult soft-tissue sarcomas: a lesson in humility.

Keedy VL.

Oncology (Williston Park). 2015 Jan;29(1):53-4. No abstract available.


Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.

Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH.

Exp Hematol Oncol. 2014 Nov 7;3(1):26. doi: 10.1186/2162-3619-3-26. eCollection 2014.


Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.

Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM.

Case Rep Oncol Med. 2014;2014:341980. doi: 10.1155/2014/341980. Epub 2014 Sep 25.


A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.

Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46. doi: 10.1007/s00280-014-2576-8. Epub 2014 Sep 12.


Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W.

Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.


Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.

Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L.

J Thorac Oncol. 2014 Apr;9(4):559-62. doi: 10.1097/JTO.0000000000000079.


Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC.

Eur J Clin Pharmacol. 2013 Dec;69(12):2073-81. doi: 10.1007/s00228-013-1580-y. Epub 2013 Aug 30.


Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J.

Clin Cancer Res. 2013 Jun 1;19(11):3078-87. doi: 10.1158/1078-0432.CCR-12-3051. Epub 2013 Apr 16.


Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG.

Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8.


Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA.

AJR Am J Roentgenol. 2013 Mar;200(3):475-83. doi: 10.2214/AJR.12.9049. Review. Erratum in: AJR Am J Roentgenol. 2013 May;200(5):1174.


Composite uterine neoplasm with embryonal rhabdomyosarcoma and primitive neuroectodermal tumor components: rhabdomyosarcoma with divergent differentiation, variant of primitive neuroectodermal tumor, or unique entity?

Cate F, Bridge JA, Crispens MA, Keedy VL, Troutman A, Coffin CM, Fadare O.

Hum Pathol. 2013 Apr;44(4):656-63. doi: 10.1016/j.humpath.2012.09.008. Epub 2012 Dec 21.


Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM.

Cancer Sci. 2012 Dec;103(12):2173-80. doi: 10.1111/cas.12037. Epub 2012 Nov 15.


Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.

Keedy VL.

Onco Targets Ther. 2012;5:153-60. doi: 10.2147/OTT.S19055. Epub 2012 Aug 22.


Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd.

Cancer Chemother Pharmacol. 2012 Nov;70(5):699-705. doi: 10.1007/s00280-012-1960-5. Epub 2012 Sep 2.


Nuclear p63 expression in osteoblastic tumors.

Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM.

Tumour Biol. 2012 Oct;33(5):1639-44. doi: 10.1007/s13277-012-0419-y. Epub 2012 May 25.


Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.

Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH.

Clin Lung Cancer. 2013 Jan;14(1):14-8. doi: 10.1016/j.cllc.2012.03.008. Epub 2012 May 15.


Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM.

Hum Pathol. 2012 Oct;43(10):1711-8. doi: 10.1016/j.humpath.2011.12.021. Epub 2012 Apr 18.


Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy.

Cates JM, Black J, Wolfe CC, Shinohara ET, Holt GE, Keedy VL, Hande KR, Homlar KC, Halpern JL, Schwartz HS, Troutman A, Coffin CM.

Hum Pathol. 2012 Sep;43(9):1418-24. doi: 10.1016/j.humpath.2011.11.002. Epub 2012 Mar 8.


American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G.

J Clin Oncol. 2011 May 20;29(15):2121-7. doi: 10.1200/JCO.2010.31.8923. Epub 2011 Apr 11.


Synchronous bone marrow metastasis from primary splenic angiosarcoma.

Datta J, Toro TZ, Keedy VL, Merchant NB.

Am Surg. 2010 Sep;76(9):E160-2. No abstract available.


Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma.

Tatsas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, Kelley MC, Cates JM.

J Cutan Pathol. 2010 Aug;37(8):901-6. doi: 10.1111/j.1600-0560.2010.01512.x. Epub 2010 Feb 8.


Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.

Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ, Cates JM.

J Pathol. 2010 Apr;220(5):608-17. doi: 10.1002/path.2679.


Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.

Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB Jr, Sandler AB, Shyr Y, Lu B.

Oncologist. 2009 Nov;14(11):1106-15. doi: 10.1634/theoncologist.2009-0130. Epub 2009 Nov 6.


Cyclooxygenase 2 expression in soft tissue leiomyosarcoma.

Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, Keedy VL, Cates JM.

Anticancer Res. 2009 Aug;29(8):2913-7.


Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma.

Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Cates JM.

Mod Pathol. 2009 Nov;22(11):1432-8. doi: 10.1038/modpathol.2009.113. Epub 2009 Jul 24.


Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597.

Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP.

J Clin Oncol. 2008 Sep 1;26(25):4166-71. doi: 10.1200/JCO.2007.15.6927.


Does gefitinib shorten lung cancer survival? Chaos redux.

Keedy VL, Arteaga CL, Johnson DH.

J Clin Oncol. 2008 May 20;26(15):2428-30. doi: 10.1200/JCO.2008.16.0374. Epub 2008 Mar 31. No abstract available.


Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Keedy VL, Sandler AB.

Cancer Sci. 2007 Dec;98(12):1825-30. Epub 2007 Sep 24. Review.


Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.

Keedy VL, Berlin J.

Curr Treat Options Oncol. 2006 Sep;7(5):381-8. Review.




JAMA. 1965 May 17;192:613-5. No abstract available.


Supplemental Content

Support Center